Kim joined Elicio Therapeutics as Senior Director of Clinical Operations in December 2021. She brings 20+ years of clinical research experience in multiple therapeutic areas in a wide variety of settings, including biotechnology, mid-size pharmaceutical, site level and CROs.
Most recently, Kim oversaw Clinical Operations for the lead product candidate at Edgewise Therapeutics. Previously, she managed a global registrational study at Celsion Corporation and prior to that several Phase 1 and 2 studies as a Project Director at Precision Oncology. Before joining Precision, Kim was the third employee in the Clinical Operations Department at Celator Pharmaceuticals and led the CPX-351 program from 2006 until 2016. After Jazz Pharmaceuticals acquired Celator in 2016, Kim was an integral part of the NDA submission and subsequent approval of Vyxeos(R).
Kim holds a Bachelor of Arts degree in Crime, Law and Justice from Pennsylvania Sate University.
In her free time, Kim loves hanging out with family and friends, being a ‘crazy cat lady‘ and also playing tennis. She is actively involved in her maintaining her historical hometown’s history by restoring her 170 year old “Underground Railroad House” and presiding over the Library Board of Trustees.